R.S.H. has received consulting fees from AbbVie, AstraZeneca, Bolt Biotherapeutics, Bristol Myers Squibb, Candel Therapeutics, Checkpoint Therapeutics, Cybrexa Therapeutics, DynamiCure, Eli Lilly and Company, EMD Serono, Genentech, Gilead, I-Mab, Immunocore, Janssen, Merck, NextCure, Normunity, Novartis, Pfizer, Regeneron Pharmaceuticals, Roche, Sanofi, and Seattle Genetics; and research funding from AstraZeneca, Eli Lilly and Company, Genentech/Roche and Merck. R.S.H. is on the Board of Directors of Immunocore. L.C. has received research funding from Normunity; and has been a scientific founder/board member/observer and/or advisor for Chia Tai Tian Qing Pharm, DynamiCure, NextCure, Normunity, OncoC4, Tcelltech, and Zai Lab in the past 12 months.